Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment. Abs#2000 #ACR20 @RheumNow https://t.co/lt8xDT4Ne8

• Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Me…

Which DMARD would you use in an RA pt Rx naive pt with mod dz activity and who has RA lung dz? #acr20 @RheumNow

Which JAKi will you use after MTX failure? #acr20 @rheumnow

Which biologic will you use after MTX and TNF failure for RA pts? #acr20 @rheumnow

Large cohort of older RA pts newly rx w/HCQ or MTX: 👉~2-fold ⬆ risk of VTE – both PE and DVT- among patients newly treated with MTX vs. HCQ. @RheumNow #ACR20 abs#2000 @DanielHSolomon https://t.co/ZnDuMhTMYF

HCQ not associated with ⬆ incidence of cardiac dse in this cohort of RA pts. We should continue using it. Benefits >>>risks. @RheumNow #ACR20 abs1999 https://t.co/zYpbX0CsR1

NEW ACR2020 Draft Guidelines for the Pharmacologic Treatment of RA All the guidelines in 2 tables! 1. MTX 1st, oral > SC 2. Minimize GC! 3. TTT TTT TTT 4. Biologic/tsDMARD > Triple Tx 5. Taper MTX 1st Close to my practice; suspect will be controversial! #ACR20 #ACRambassador https://t.co/iFSlq1H65V

Rheum Now shares Day 3 highlights from #ACR20. https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh

• https://bit.ly/2IhSKj0

Abst#1717 confirms that early start of csDMARDs as 1st line tx & keeping ts/bDMARD as 2nd line tx (or more) is associated w/ a favorable outcome at 10 yrs in the ESPOIR cohort (a French multi-center cohort that followed patients w/ early RA). #ACR20 @RheumNow https://t.co/bzZiShCF97

This - very cool. Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see! #ACR20 ABST1995 @RheumNow https://t.co/QZ8npob2H9 https://t.co/fRlFwIHqky

• https://twitter.com/RichardPAConway/status/1325821699053383683